| Identification | More | [Name]
L-Lysine monoacetate | [CAS]
57282-49-2 | [Synonyms]
H-LYS-OH ACOH
L-LYS AC
L-LYSINE AC
L-LYSINE ACETATE
L-LYSINE ACETATE SALT
L-Lysine monoacetate
LYSINE ACETATE
(S)-2,6-DIAMINOHEXANOIC ACID
(s)-2,6-diaminohexanoic acid acetate salt
L-LYSINE ACETATE USP
L-LYSINE ACETATE USP STANDARD
LYSINEACETATE,USP
(S)-2,6-Diaminohexanoic acid, L-Lysine acetate salt
Lysine acetate salt | [EINECS(EC#)]
260-664-4 | [Molecular Formula]
C8H18N2O4 | [MDL Number]
MFCD00039069 | [Molecular Weight]
206.24 | [MOL File]
57282-49-2.mol |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
Freely soluble in water, very slightly soluble in ethanol (96 per cent). | [form ]
neat | [color ]
White to off-white | [InChI]
InChI=1/C6H14N2O2.C2H4O2/c7-4-2-1-3-5(8)6(9)10;1-2(3)4/h5H,1-4,7-8H2,(H,9,10);1H3,(H,3,4)/t5-;/s3 | [InChIKey]
RRNJROHIFSLGRA-USHJBNIQNA-N | [SMILES]
[C@@H](N)(C(=O)O)CCCCN.C(=O)(O)C |&1:0,r| | [LogP]
-1.036 (est) | [Uses]
Amino acid. | [CAS DataBase Reference]
57282-49-2(CAS DataBase Reference) | [EPA Substance Registry System]
57282-49-2(EPA Substance) |
| Hazard Information | Back Directory | [Chemical Properties]
Solid | [General Description]
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. L-Lysine is an essential proteinogenic α-amino acid, containing basic side chain and is hydrophilic in nature. L-Lysine is actively used in the form of its acetate salt. It serves as a precursor for secondary metabolites, such as β-lactam antibiotics. It also serves as a precursor for the biosynthesis of α-aminoadipic acid. | [Biochem/physiol Actions]
L-Lysine is an essential proteinogenic α amino acid used in a wide range of applications including as a supplement in cell culture media; a substrate of enzymes such as L-lysine oxidase (EC 1.4.3.14); a component of poly-lysine polymers; and a substrate for oxidation and glycation mechanism studies. | [in vivo]
L-Lysine acetate (40 μg/kg; p.o.) ameliorates arterial calcification in adenine rats and protects the femora from osteoporotic changes in adenine rats[1].
L-Lysine acetate (10 and 400 mg/kg; i.g. and p.o.; Male mice) inhibits pancreatic tissue damage[2]. | Animal Model: | Male mice[2] | | Dosage: | 10 and 400 mg/kg | | Administration: | Intraperitoneal injection and oral administration; for 15 days. | | Result: | Inhibited the release of the inflammatory cytokine IL-6 and enhance antioxidant activity. |
| [IC 50]
Microbial Metabolite; Human Endogenous Metabolite |
|
|